Mackenzie Financial Corp Boosts Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Mackenzie Financial Corp boosted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2,278.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 44,548 shares of the specialty pharmaceutical company’s stock after acquiring an additional 42,675 shares during the quarter. Mackenzie Financial Corp’s holdings in Jazz Pharmaceuticals were worth $5,479,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in Jazz Pharmaceuticals by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock valued at $825,705,000 after acquiring an additional 29,960 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Jazz Pharmaceuticals by 7.5% in the 1st quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company’s stock worth $408,654,000 after buying an additional 184,124 shares during the period. State Street Corp lifted its holdings in shares of Jazz Pharmaceuticals by 1.8% in the 2nd quarter. State Street Corp now owns 2,372,395 shares of the specialty pharmaceutical company’s stock worth $294,106,000 after buying an additional 42,703 shares during the period. LSV Asset Management lifted its holdings in shares of Jazz Pharmaceuticals by 2.4% in the 3rd quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company’s stock worth $307,055,000 after buying an additional 55,630 shares during the period. Finally, FMR LLC lifted its holdings in shares of Jazz Pharmaceuticals by 8.1% in the 3rd quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company’s stock worth $172,560,000 after buying an additional 100,349 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 1,936 shares of the stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the transaction, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CAO Patricia Carr sold 1,936 shares of the stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the transaction, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Philip L. Johnson acquired 12,000 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was purchased at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now directly owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ:JAZZ opened at $109.94 on Friday. The business’s 50-day moving average is $119.81 and its 200 day moving average is $122.48. Jazz Pharmaceuticals plc has a 1 year low of $106.61 and a 1 year high of $146.70. The firm has a market capitalization of $6.93 billion, a P/E ratio of 17.96, a P/E/G ratio of 1.51 and a beta of 0.59. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.24 and a quick ratio of 1.85.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.01 billion. On average, research analysts predict that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on JAZZ. Barclays lowered their target price on Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, March 1st. JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, March 22nd. Royal Bank of Canada reiterated an “outperform” rating and issued a $195.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. Stifel Nicolaus upped their price objective on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research note on Friday, March 15th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $195.08.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.